[HTML][HTML] Competing endogenous RNA networks in human cancer: hypothesis, validation, and perspectives

C Yang, D Wu, L Gao, X Liu, Y Jin, D Wang, T Wang… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Non-coding RNAs represent a majority of the human transcriptome. However, less is known
about the functions and regulatory mechanisms of most non-coding species. Moreover, little …

[HTML][HTML] Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho… - Annals of …, 2022 - Elsevier
Background Combined therapy with dabrafenib plus trametinib was approved in several
countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an …

[HTML][HTML] The multifaceted anti-cancer effects of BRAF-inhibitors

L Croce, F Coperchini, F Magri, L Chiovato… - Oncotarget, 2019 - ncbi.nlm.nih.gov
The BRAF gene is commonly involved in normal processes of cell growth and differentiation.
The BRAF (V600E) mutation is found in several human cancer, causing an increase of cell …

BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer

GS Falchook, M Millward, D Hong, A Naing… - Thyroid, 2015 - liebertpub.com
Background: Mutations of v-raf murine sarcoma viral oncogene homolog B (BRAF) are
commonly identified in papillary and anaplastic thyroid carcinoma and are associated with …

Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules

S Beaudenon-Huibregtse, EK Alexander, RB Guttler… - Thyroid, 2014 - liebertpub.com
Background: Molecular testing for oncogenic gene mutations and chromosomal
rearrangements plays a growing role in the optimal management of thyroid nodules, yet …

[HTML][HTML] Role of lncRNA BANCR in human cancers: an updated review

BM Hussen, T Azimi, A Abak, HJ Hidayat… - Frontiers in cell and …, 2021 - frontiersin.org
Being located in a gene desert region on 9q21. 11-q21. 12, BRAF-activated non-protein
coding RNA (BANCR) is an lncRNA with 693 bp length. It has been discovered in 2012 in a …

[HTML][HTML] Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability

S Hong, Y Xie, Z Cheng, J Li, W He, Z Guo, Q Zhang… - Oncogene, 2022 - nature.com
Papillary thyroid carcinoma (PTC) is heterogeneous and its molecular characteristics remain
elusive. We integrated transcriptomic sequencing, genomic analysis and clinicopathologic …

Clinicopathologic Implications of the BRAFV600E Mutation in Papillary Thyroid Cancer: A Subgroup Analysis of 3130 Cases in a Single Center

JY Lim, SW Hong, YS Lee, BW Kim, CS Park… - Thyroid, 2013 - liebertpub.com
Background: The BRAF mutation has been shown to be associated with aggressive
clinicopathologic characteristics of papillary thyroid cancer (PTC). However, several studies …

[HTML][HTML] Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas

CM Beltrami, MB Dos Reis, MC Barros-Filho… - Clinical …, 2017 - Springer
Background Papillary thyroid carcinoma (PTC) is a common endocrine neoplasm with a
recent increase in incidence in many countries. Although PTC has been explored by gene …

[HTML][HTML] B-Raf and the inhibitors: from bench to bedside

T Huang, M Karsy, J Zhuge, M Zhong, D Liu - Journal of hematology & …, 2013 - Springer
The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase
(MAPK) signaling pathway and has been implicated in the pathogenesis of a variety of …